Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16474608 | 0.93 | BRD9 (0.44) | KDM4EALDH1A1MAPTCYP11B2MKNK1 | |
| SCHEMBL16474572 | 0.81 | GAA (0.48) | NPC1RAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16474618 | 0.81 | BRD4 (0.37) | BRD4MAP3K5 | |
| SCHEMBL16474996 | 0.80 | BRD4 (0.40) | ALDH1A1GAASMN1; SMN2MKNK1MKNK2 | |
| SCHEMBL10059850 | 0.79 | BRD4 (0.48) | KDM4EALDH1A1MKNK1MKNK2BRD4 | |
| SCHEMBL10059864 | 0.78 | DRD2 (0.42) | MAPTMKNK1MKNK2CCNCCDK8 | |
| SCHEMBL16474629 | 0.78 | CREBBP (0.42) | MKNK1MKNK2BRD4CREBBP | |
| SCHEMBL16474625 | 0.77 | WNT1 (0.42) | MKNK1MKNK2BRD4CREBBP | |
| SCHEMBL18077693 | 0.77 | BRD4 (0.38) | CYP11B2MKNK1MKNK2BRD4CREBBP | |
| SCHEMBL13075773 | 0.77 | LCK (0.41) | MKNK1MKNK2METBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903991-B1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10376497-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10233195-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2015153683-A1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
| US-10544161-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
| US-10233195-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
| US-10376497-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | NPC1 2565/4885RAB9A 2353/4885KDM4E 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.